AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
